Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010051/S023

IMMULITE 2000 Systems Total Antibodies to Hepatitis B Core Antigen (Anti-HBc)

Siemens Healthcare Diagnostics Products, Ltd. · Decision date Aug 4, 2025

FDA DECISIONP010051/S023

What did the FDA decide?

FDA records P010051/S023 as a supplement to PMA P010051, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 4, 2025.

FDA approval order statement

an internal site to internal site transfer of a manufacturing process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Microbiology
Decision date
Aug 4, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P010051/S023
Regulatory pathway
PMA supplement
Product code
LOM
Decision code
OK30
Decision date
Aug 4, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen).

Product code
LOM
FDA device class
2

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P010051/S023 received

    Application receipt date recorded by FDA.

  2. P010051/S023 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P010051. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code LOM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Healthcare Diagnostics Products, Ltd.

Headquarters
Not reported
FDA applicant address
Glyn Rhonwy, Llanberis, LL55 4EL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records